Details
Description
In this report, we identified pregnancies exposed to ixekizumab (an interleukin-17A monoclonal antibody) and comparator drugs of interest among females regardless of indication and among females with approved ixekizumab indications in the Sentinel Distributed Database (SDD). The study period includes data from March 22, 2016 to June 30, 2021. We distributed this request to six Sentinel Data Partners on March 3, 2022.